About this trial
Postoperative endothelial cell loss following Descemet stripping endothelial keratoplasty (DSEK) remains a well-recognized clinical concern, with long-term follow-up demonstrating approximately 50% reduction in endothelial cell density by 5 years. Compounding this challenge, the critical shortage of corneal donors has severely limited the expansion of corneal transplantation programs in developing countries. In conventional penetrating keratoplasty, only the central 7-mm optical zone is typically harvested, whereas the peripheral donor tissue-whose endothelial cells are believed to exhibit superior viability-is routinely discarded.
To address these limitations, we describe the first-in-human use of three residual peripheral donor tissue segments, obtained after conventional keratoplasty, which were combined to perform corneal endothelial transplantation. This innovative approach substantially enhanced donor tissue utilization. Postoperatively, the patient achieved sustained corneal transparency with visual acuity improving from 20/500 to 20/50. Notably, the intersegmental gaps resolved progressively over time.
Extending this proof-of-concept case, we subsequently investigated the long-term stability and safety of residual donor tissue endothelial keratoplasty for bullous keratopathy, with comprehensive evaluation of postoperative visual acuity, intraocular pressure, corneal endothelial cell density, and refractive outcomes. This study aims to establish evidence-based support for the safety and efficacy of utilizing residual graft tissue in corneal endothelial transplantation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with bullous keratopathy of various etiologies, with a corneal thickness of ≥650 μm, refractory to medical treatment.
Aged ≥18 years.
The subject or their legally authorized guardian voluntarily consents to participate in this study and signs the informed consent form, with good compliance and willingness to attend follow-up visits.
Disqualifiers
Loss of vision in the fellow eye.
Corneal or ocular surface infection within 30 days prior to enrollment.
Severe dry eye, with Schirmer's test < 5 mm.
Concurrent diseases that may affect the transplantation or prognosis, such as advanced glaucoma or retinal diseases.
Trial design
Single group
Treatments tested in this trial
Endothelial keratoplasty using residual donor tissue
Procedure/SurgeryEndothelial keratoplasty using residual donor tissue from previous corneal transplantation
Treatment groups
Trial outcomes
Primary outcomes
Corneal thickness
Corneal thickness was measured preoperatively and postoperatively using an iVue OCT (OPTOVUE) or another OCT instrument, and the changes were compared.
Secondary outcomes
Best-corrected visual acuity (BCVA)
Preoperative and postoperative visual acuity was assessed using the ETDRS chart.
Spherical equivalent (SE)
Preoperative and postoperative SE was measured using a phoropter and an autorefractor, and differences before and after surgery as well as between the two groups were compared.
Corneal edema and opacity
The degree of corneal edema and opacity was examined by slit-lamp microscopy.
Corneal endothelial cell count
Postoperative corneal endothelial cell density was measured using laser confocal microscopy (Heidelberg Engineering, Germany) or a corneal endothelial specular microscope, and changes were compared.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: